AU2007334502B2 - Compositions and methods to treat muscular & cardiovascular disorders - Google Patents

Compositions and methods to treat muscular & cardiovascular disorders Download PDF

Info

Publication number
AU2007334502B2
AU2007334502B2 AU2007334502A AU2007334502A AU2007334502B2 AU 2007334502 B2 AU2007334502 B2 AU 2007334502B2 AU 2007334502 A AU2007334502 A AU 2007334502A AU 2007334502 A AU2007334502 A AU 2007334502A AU 2007334502 B2 AU2007334502 B2 AU 2007334502B2
Authority
AU
Australia
Prior art keywords
mir
sirna
double
rna
stranded rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007334502A
Other languages
English (en)
Other versions
AU2007334502A1 (en
Inventor
Iwan Beuvink
Jonathan Hall
Matthias Mueller
Martina Schinke-Braun
Christian Schnell
Fabrizio Serluca
Jan Weiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2007334502A1 publication Critical patent/AU2007334502A1/en
Application granted granted Critical
Publication of AU2007334502B2 publication Critical patent/AU2007334502B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2007334502A 2006-12-14 2007-12-13 Compositions and methods to treat muscular & cardiovascular disorders Ceased AU2007334502B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86993706P 2006-12-14 2006-12-14
US60/869,937 2006-12-14
PCT/US2007/025535 WO2008076324A2 (en) 2006-12-14 2007-12-13 Compositions and methods to treat muscular & cardiovascular disorders

Publications (2)

Publication Number Publication Date
AU2007334502A1 AU2007334502A1 (en) 2008-06-26
AU2007334502B2 true AU2007334502B2 (en) 2011-12-15

Family

ID=39536897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007334502A Ceased AU2007334502B2 (en) 2006-12-14 2007-12-13 Compositions and methods to treat muscular & cardiovascular disorders

Country Status (11)

Country Link
US (3) US20100280094A1 (OSRAM)
EP (1) EP2104733A2 (OSRAM)
JP (3) JP2010512747A (OSRAM)
KR (1) KR20090098818A (OSRAM)
CN (2) CN102604951A (OSRAM)
AU (1) AU2007334502B2 (OSRAM)
BR (1) BRPI0719995A2 (OSRAM)
CA (1) CA2672606A1 (OSRAM)
EA (2) EA200900782A1 (OSRAM)
MX (1) MX2009006310A (OSRAM)
WO (1) WO2008076324A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009001281A (es) 2006-08-01 2009-04-16 Univ Texas Identificacion de un micro-arn que activa la expresion de la cadena pesada de beta-miosina.
CA2694928A1 (en) 2007-07-31 2009-02-05 Board Of Regents, The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
JP5943608B2 (ja) 2009-02-04 2016-07-05 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 心臓障害の治療におけるｍｉｒ−２０８およびｍｉｒ−４９９の二重ターゲティング
IE20090047A1 (en) * 2009-02-26 2010-09-29 Nat Univ Ireland Protein targets in disease
EP2703501A1 (en) * 2009-03-12 2014-03-05 Brandeis University Reagents and Methods for PCR
WO2012083005A2 (en) 2010-12-15 2012-06-21 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
KR20140091688A (ko) 2011-10-06 2014-07-22 미라젠 세러퓨틱스 인코포레이티드 마이크로rna 조절에 의한 전신 에너지 항상성의 제어
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
AU2013331434B2 (en) * 2012-10-15 2019-08-08 Ionis Pharmaceuticals, Inc. Compositions for modulating C90RF72 expression
US9637738B2 (en) * 2013-04-10 2017-05-02 Reveragen Biopharma, Inc. Methods and agents to increase therapeutic dystrophin expression in muscle
RU2748426C2 (ru) 2013-10-11 2021-05-25 Ионис Фармасьютикалз, Инк. Композиции для модуляции экспрессии c90rf72
AR101449A1 (es) * 2014-08-04 2016-12-21 Miragen Therapeutics Inc Inhibidores de myh7b y usos de los mismos
SG11201705907XA (en) 2015-01-20 2017-08-30 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof
EP3722424A1 (en) 2015-04-16 2020-10-14 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
CN106148519A (zh) * 2016-07-05 2016-11-23 无锡市第二人民医院 一种microRNA‑499的快速检测方法
US12054711B2 (en) 2017-07-14 2024-08-06 City Of Hope Meta-stable oligonucleotides junctions for delivery of therapeutics
WO2019033079A1 (en) * 2017-08-10 2019-02-14 City Of Hope CONDITIONAL RNAIDS AND THEIR USES IN THE TREATMENT OF CARDIAC HYPERTROPHY
KR102281710B1 (ko) 2021-02-19 2021-07-28 조기정 에어튜브를 이용한 선박 안전장치
CN119246849B (zh) * 2024-12-09 2025-03-14 上海基灵生物科技有限公司 一种检测犬心脏损伤的试剂盒及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
PT98562B (pt) * 1990-08-03 1999-01-29 Sanofi Sa Processo para a preparacao de composicoes que compreendem sequencias de nucleo-sidos com cerca de 6 a cerca de 200 bases resistentes a nucleases
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
JP3516167B2 (ja) * 1992-12-08 2004-04-05 ローム株式会社 タンタルコンデンサチップの製造方法
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
ES2559828T3 (es) * 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
WO2005021800A2 (en) * 2003-08-22 2005-03-10 Sirna Therapeutics, Inc. Detection and quantitation of nucleic acid molecules in biological samples
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
CA2603881A1 (en) * 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
US20070092882A1 (en) * 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
ES2612903T3 (es) * 2006-01-10 2017-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Moléculas de ácido nucleico y colecciones de las mismas, su aplicación e identificación
MX2009001281A (es) * 2006-08-01 2009-04-16 Univ Texas Identificacion de un micro-arn que activa la expresion de la cadena pesada de beta-miosina.
CA2694928A1 (en) * 2007-07-31 2009-02-05 Board Of Regents, The University Of Texas System Micro-rnas that control myosin expression and myofiber identity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAGOS-QUINTANA, M. et al. RNA. February 2003, Vol.9, No.2, pages 175-179. *

Also Published As

Publication number Publication date
EA201101361A1 (ru) 2012-11-30
KR20090098818A (ko) 2009-09-17
US20100280094A1 (en) 2010-11-04
CN101563458A (zh) 2009-10-21
WO2008076324A2 (en) 2008-06-26
JP2012131812A (ja) 2012-07-12
EP2104733A2 (en) 2009-09-30
JP2010512747A (ja) 2010-04-30
BRPI0719995A2 (pt) 2014-03-18
AU2007334502A1 (en) 2008-06-26
CN102604951A (zh) 2012-07-25
JP2012019789A (ja) 2012-02-02
WO2008076324A3 (en) 2009-04-09
CA2672606A1 (en) 2008-06-26
EA200900782A1 (ru) 2009-12-30
US20120114744A1 (en) 2012-05-10
MX2009006310A (es) 2009-07-22
US20120041052A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
AU2007334502B2 (en) Compositions and methods to treat muscular & cardiovascular disorders
EP2208499A1 (en) Nucleic acid capable of regulating the proliferation of cell
KR20110128838A (ko) 심장 질환 치료에서 ｍｉｒ－208 및 ｍｉｒ－499의 이중 표적화
US20100088775A1 (en) Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same
EP2683411B1 (en) Methods of using microrna-26a to promote angiogenesis
US9885042B2 (en) miR-92 inhibitors and uses thereof
WO2011019074A1 (ja) 細胞または臓器の線維化を制御する核酸
AU2013327393B2 (en) Modulation of RNA activity and vascular permeability
US7807652B2 (en) Modulation of eIF4E-BP2 expression
WO2022026648A1 (en) Inhibition of incexact1 to treat heart disease
US9334498B2 (en) Methods and compositions for modulating MIR-204 activity
US20100305195A1 (en) microrna mediator of cardiomyopathy and heart failure
US20220282257A1 (en) Method of modulating adiposity
WO2024098061A2 (en) Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
WO2021062251A2 (en) Targeting rlim to modulate body weight and obesity
WO2011010737A1 (ja) マイクロｒｎａ切断用のガイド核酸

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired